Protagonist Therapeutics PTGX Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$114.71M+11.9% | -$130.15M-383% | $45.91M-11.8% | $52.04M-7.4% | $56.19M-79.6% | ||
| $1.45M+13.1% | $1.28M+25.2% | $1.02M+14.6% | $892K+7.6% | $829K+0.4% | ||
| $46.69M+1.6% | $45.97M+3.6% | $44.37M+0.9% | $43.97M+4.7% | $42M+11.8% | ||
| $5.8M+43.8% | $4.03M— | —— | —— | —— | ||
| —— | —— | —— | —— | -$4.66M-209% | ||
| $3.38M+40.2% | $2.41M+17.8% | $2.05M-36.3% | $3.21M-22.2% | $4.12M+0.8% | ||
| —— | —— | —— | —— | —— | ||
| -$18.79M+10.6% | -$21.02M— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $1.26M-20.8% | $1.59M-9.5% | $1.76M-28.1% | $2.44M+47.3% | $1.66M+22.4% | ||
| $401.51M-26.5% | $546.59M-1.8% | $556.72M-15.9% | $662.27M-14.0% | $770.07M+23.9% | ||
| $535.35M+8.8% | $491.84M+10.6% | $444.6M+11.0% | $400.68M+9.8% | $364.77M+12.7% | ||
| —— | —— | —— | —— | -$399.96M-33.5% | ||
| —— | —— | —— | —— | —— | ||
| $34.8M+52.2% | $22.86M-5.0% | $24.06M-21.0% | $30.45M+1.2% | $30.1M+16.4% | ||
| —— | —— | —— | -$187.04M-468% | -$32.92M+63.2% | ||
| —— | $3.69M+17.2% | $3.15M+20.7% | $2.61M+26.1% | $2.07M+35.4% | ||
| $5.96M-17.5% | $7.22M-16.5% | $8.65M-11.8% | $9.8M+2.6% | $9.55M+7.6% | ||
| $5.8M+43.8% | $4.03M— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | -$4.66M-209% | ||
| $3.38M+40.2% | $2.41M+17.8% | $2.05M-36.3% | $3.21M-22.2% | $4.12M+0.8% | ||
| —— | —— | —— | —— | -$300.04M-294% | ||
| $1.46M-8.2% | $1.59M-4.4% | $1.66M-15.7% | $1.97M-4.0% | $2.05M-0.7% | ||
| $535.35M+8.8% | $491.84M+10.6% | $444.6M+11.0% | $400.68M+9.8% | $364.77M+12.7% | ||
| —— | —— | —— | —— | —— | ||
| $34.8M+49.1% | $23.34M-4.9% | $24.54M-20.7% | $30.93M+1.2% | $30.58M+15.6% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | $3.69M+17.2% | $3.15M+20.7% | $2.61M+26.1% | $2.07M+35.4% | ||
| —— | —— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Protagonist Therapeutics generate?
- Protagonist Therapeutics (PTGX) generated $317.6M in operating cash flow over the trailing twelve months.
- What is Protagonist Therapeutics's free cash flow?
- After $1.3M of capital expenditures, Protagonist Therapeutics's free cash flow was $316.6M over the trailing twelve months, up 364.9% year over year.
- Where does Protagonist Therapeutics's cash flow data come from?
- Every line is extracted from Protagonist Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
